JP6636453B2 - 対象のポリペプチドを組換えによって発現するための新規脊椎動物細胞および方法 - Google Patents

対象のポリペプチドを組換えによって発現するための新規脊椎動物細胞および方法 Download PDF

Info

Publication number
JP6636453B2
JP6636453B2 JP2016565268A JP2016565268A JP6636453B2 JP 6636453 B2 JP6636453 B2 JP 6636453B2 JP 2016565268 A JP2016565268 A JP 2016565268A JP 2016565268 A JP2016565268 A JP 2016565268A JP 6636453 B2 JP6636453 B2 JP 6636453B2
Authority
JP
Japan
Prior art keywords
matriptase
cell
polypeptide
cells
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016565268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514484A (ja
JP2017514484A5 (enExample
Inventor
ラウクス，ホルジャー
ロマンド，サンドリーン
ボデンドルフ，ウルスラ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53682742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6636453(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017514484A publication Critical patent/JP2017514484A/ja
Publication of JP2017514484A5 publication Critical patent/JP2017514484A5/ja
Application granted granted Critical
Publication of JP6636453B2 publication Critical patent/JP6636453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
JP2016565268A 2014-04-29 2015-04-29 対象のポリペプチドを組換えによって発現するための新規脊椎動物細胞および方法 Active JP6636453B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461985589P 2014-04-29 2014-04-29
US61/985,589 2014-04-29
US201461994310P 2014-05-16 2014-05-16
US61/994,310 2014-05-16
PCT/IB2015/053110 WO2015166427A2 (en) 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Publications (3)

Publication Number Publication Date
JP2017514484A JP2017514484A (ja) 2017-06-08
JP2017514484A5 JP2017514484A5 (enExample) 2018-06-14
JP6636453B2 true JP6636453B2 (ja) 2020-01-29

Family

ID=53682742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565268A Active JP6636453B2 (ja) 2014-04-29 2015-04-29 対象のポリペプチドを組換えによって発現するための新規脊椎動物細胞および方法

Country Status (17)

Country Link
US (2) US11512335B2 (enExample)
EP (3) EP4332231A3 (enExample)
JP (1) JP6636453B2 (enExample)
KR (1) KR102307278B1 (enExample)
CN (1) CN106255749A (enExample)
AU (1) AU2015254913B2 (enExample)
CA (1) CA2947198C (enExample)
DK (2) DK3536776T5 (enExample)
ES (2) ES2968879T3 (enExample)
IL (1) IL248184B (enExample)
LT (2) LT3137595T (enExample)
MX (1) MX368664B (enExample)
PL (2) PL3137595T3 (enExample)
PT (2) PT3137595T (enExample)
RU (1) RU2710726C2 (enExample)
SG (1) SG11201608358VA (enExample)
WO (1) WO2015166427A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
WO2020081328A1 (en) * 2018-10-15 2020-04-23 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
PE20221416A1 (es) 2019-09-18 2022-09-20 Novartis Ag Proteinas de fusion nkg2d y sus usos
US20210244821A1 (en) 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
EP4150085A1 (en) * 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
CN115551519A (zh) * 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
EP4526462A1 (en) * 2022-05-19 2025-03-26 Novartis AG Improved protein production using mirna technology

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
AU572108B2 (en) 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU2001278488A1 (en) 2000-07-25 2002-02-05 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
CN100513414C (zh) * 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
MXPA05003493A (es) * 2002-10-02 2005-09-30 Catalyst Biosciences Metodos para generar y seleccionar proteasas con especificidad alterada.
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
CN102443627B (zh) * 2004-08-10 2014-10-29 加的夫生物学有限公司 用于乳腺癌的预后的试剂盒
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
ES2546086T3 (es) 2007-12-21 2015-09-18 Novartis Ag Sistema de selección en un cultivo de células eucariotas basado en un gen receptor de folato unido a la membrana
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CA2753814C (en) 2009-02-27 2018-07-31 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
PT2563904E (pt) 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
ES2676412T3 (es) 2011-06-02 2018-07-19 Socpra Sciences Santé Et Humaines S.E.C. Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus
CN110078827A (zh) * 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
SG11201408554QA (en) * 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Also Published As

Publication number Publication date
EP3137595B1 (en) 2019-03-13
ES2968879T3 (es) 2024-05-14
CN106255749A (zh) 2016-12-21
IL248184B (en) 2021-03-25
IL248184A0 (en) 2016-11-30
EP3536776A1 (en) 2019-09-11
AU2015254913A1 (en) 2016-10-27
DK3536776T3 (da) 2024-01-15
DK3137595T3 (da) 2019-06-17
EP4332231A3 (en) 2024-05-29
PL3536776T3 (pl) 2024-03-25
MX368664B (es) 2019-10-10
LT3137595T (lt) 2019-06-25
WO2015166427A2 (en) 2015-11-05
BR112016024534A2 (pt) 2017-10-10
AU2015254913B2 (en) 2018-05-17
RU2016145928A (ru) 2018-05-29
KR20160147919A (ko) 2016-12-23
RU2016145928A3 (enExample) 2018-12-26
PT3137595T (pt) 2019-06-19
JP2017514484A (ja) 2017-06-08
EP4332231A2 (en) 2024-03-06
DK3536776T5 (da) 2024-09-02
CA2947198A1 (en) 2015-11-05
PL3137595T3 (pl) 2019-09-30
US20170044587A1 (en) 2017-02-16
SG11201608358VA (en) 2016-11-29
RU2710726C2 (ru) 2020-01-10
LT3536776T (lt) 2024-01-25
WO2015166427A3 (en) 2016-01-14
MX2016014222A (es) 2017-05-04
US11512335B2 (en) 2022-11-29
US20230323419A1 (en) 2023-10-12
ES2731246T3 (es) 2019-11-14
EP3137595A2 (en) 2017-03-08
PT3536776T (pt) 2024-01-12
EP3536776B1 (en) 2023-10-25
KR102307278B1 (ko) 2021-09-30
CA2947198C (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US20230323419A1 (en) Vertebrate cells and methods for recombinantly expressing a polypeptide of interest
AU2014369175B2 (en) Novel eukaryotic cells and methods for recombinantly expressing a product of interest
AU2014369177B2 (en) Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP4562151A1 (en) Improved production of cd39 variants
BR112016024534B1 (pt) Métodos para produzir de forma recombinante um polipeptídeo de interesse, para produzir uma célula de vertebrado isolada, e para selecionar uma célula, bem como uso de uma célula de vertebrado
US20250313878A1 (en) IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191218

R150 Certificate of patent or registration of utility model

Ref document number: 6636453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250